Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction;Botulinumtoxin in der therapie der neurogenen detrusorhyperaktivität. Konsensuspapier zum einsatz bei einer neurogenen blasenfunktionsstörung

Urologe - Ausgabe A

Volumn 46, Issue 3, 2007, Pages 293-296

  Sievert, K D ^a   Bremer, J ^b   Burgdorfer H ^c   Domurath, B ^d   Hampel, C ^e   Kutzenberger, J ^d   Seif, C ^f   Stohrer M ^g   Wefer, B ^f   Pannek, J ^h  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Abteilung für Querschnittsgelähmte   (Germany)

^c Berufsgenossenschaftliche Unfallkrankenhaus Hamburg   (Germany)

^d Werner Wicker Klinik   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Botulinum toxin A; Detrusor hyperactivity; Detrusor pressure; Neurogenic bladder; Off label use

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ANTICHOLINERGIC EFFECT; BLADDER DYSFUNCTION; BLADDER EMPTYING; BLADDER PRESSURE; CONSENSUS; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY FUNCTION; NEUROGENIC BLADDER; OFF LABEL DRUG USE; REVIEW; RISK ASSESSMENT; SURGICAL RISK;

BOTULINUM TOXIN TYPE A; GERMANY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; URINARY BLADDER, NEUROGENIC;

EID: 33947309392     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1295-8     Document Type: Review

References (46)

1. Yokoyama T, Kumon H, Smith CP et al. (2002) Botulinum toxin treatment of urethral and bladder dysfunction. Acta Med Okayama 56: 271
2. National Spinal Cord Injury Statistical Center (2005) Annual Statistical Report. National Spinal Cord Injury Statistical Center, University of Alabama, Birmingham, pp 39-42
3. Abrams P, Cardozo L, Fall M et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21: 167-178
4. Fowler CJ (2000) Intravesical treatment of overactive bladder. Urology 55(Suppl 5A): 60-64
5. Rovner ES, Wein AJ (2002) Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: A review. Eur Urol 41: 6-14
6. Horstmann M, Schaefer T, Aguilar Y et al. (2006) Neurogenic bladder treatment by doubling antimuscarinic dosage. Neurourol Urodynam 25: 441-445
7. Smith CP, Franks ME, McNeil BK et al. (2003) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169: 1896
8. Smith CP, Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171: 2128
9. Dykstra DD, Sidi AA, Scott AB et al. (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139: 919-922
10. Stöhrer M, Schurch B, Kramer G et al. (1999) Botulinum toxin-A in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 18: 401-402
11. Radziszewski P, Dobronski P, Borkowski A (2001) Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin A: A pilot study. Paper presented at: 31st Annual Meeting of the International Continence Society, Seoul, Korea
12. Zermann DH, Ishigooka M, Schubert J, Schmidt RA (2001) Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Paper presented at: 31st Annual Meeting of the International Continence Society, Seoul, Korea
13. Schulte-Baukloh H, Knispel HH (2004) Botulinumtoxin in der Urologie - eine Bestandsaufnahme. Urologe A 43: 963-975
14. Schurch B, de Seze M, Denys P et al. (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174: 196-200
15. Sahai et al. (2006) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 97: 413-414
16. Leippold T, Reitz A, Schurch B (2003) Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44: 165
17. Rackley R, Abdelmalak J (2004) Urologic applications of botulinum toxin therapy for voiding dysfunction. Curr Urol Rep 5: 381
18. Rapp DE, Lucioni A, Katz EE et al. (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63: 1071
19. Smith CP, Somogyi GT, Chancellor MB, Appell RA (2004) A case for botulinum toxin-A in idiopathic bladder overactivity. Curr Urol Rep 5: 432
20. Rajkumar GN, Conn IG (2004) Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction. Urology 64: 2-8
21. Altaweel W, Corcos J, Robichaud C (2004) Botulinum-A toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomeningocele. Eur Urol 3(Suppl 2): 170
22. Bagi P, Biering-Sorensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38: 495-498
23. Giannantoni A, Di Stasi SM, Stephen RL et al. (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 172: 240-243
24. Giannantoni A, Mearini E, Di Stasi SM et al. (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56: 79-87
25. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47: 653-659
26. Hajebrahimi S, Altaweel W, Cadoret J et al. (2005) Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 12: 2543-2546
27. Kessler TM, Danuser H, Schumacher M et al. (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24: 231-236
28. Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63: 868-872
29. Lusuardi L, Nader A, Koen M et al. (2004) Minimally invasive, safe treatment of the neurogenic bladder with botulinum-A-toxin in children with myelomeningocele. Aktuel Urol 35(1): 49-53
30. Marte A, Vessella A, Cautiero P et al. (2005) Efficacy of toxin-A Botulinum for treating intractable bladder hyperactivity in children affected by neuropathic bladder secondary to myelomeningocele: an alternative to enterocystoplasty. Minerva Pediatr 57: 35-40
31. Popat R, Apostolidis A, Kalsi V et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174(3): 984-989
32. Reitz A, Stöhrer M, Kramer G et al. (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510-515
33. Riccabona M, Koen M, Schindler M et al. (2004) Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171: 845-848
34. Richter R, Schaaf V (2002) Botulinum-A-toxin for therapy of detrusor hyperreflexia in neurogenic bladders. Aktuel Urol 33(2): 141-142
35. Schulte-Baukloh H, Knispel HH, Michael T (2002) Botulinum-A toxin in the treatment of neurogenic bladder in children. Pediatrics 110: 420-421
36. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH (2003) Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44: 139-143
37. Schurch B, Stöhrer M, Kramer G et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692-697
38. Stöhrer M, Schurch B, Kramer G et al. (2003) Botulinum toxin-A to treat detrusor hyperreflexia in spinal cord-injured patients: A long-term follow up. Aust N Z J Surg 73: A142
39. Schulte-Baukloh H, Knispel HH (2006) Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents. BJU Int 98(Suppl 1): 50-60
40. Leippold T, Reitz A, Schurch B (2003) Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol 44: 165-174
41. Haferkamp A, Schurch B, Reitz A et al. (2004) Lack of ultrastructural detrusor changes following endoscopic injection of Botulinum Toxin Type A in overactive neurogenic bladder. Eur Urol 46: 784-791
42. De Laet K, Wyndaele JJ (2005) Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 43: 397-399
43. Wyndaele JJ, Van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40: 599-600
44. Yablon SA, Daggett S, Lai F et al. (2005) The development of toxin neutralizing antibodies with Botulinum Toxin type A (BoNTA) treatment. Presented on 5th International Conference on the Basic and Therapeutic Aspects of Botulinum and Tetanus, Denver, Colorado; For poster abstract #85, see: http://www.toxins2005.org/text/abstracts.html
45. Irwin D, Milsom I, Reilly K et al. (2006) Men and women with overactive bladder symptoms report higher prevalence of depression and lower quality of life: results from the EPIC study. Paper to be presented at: 31st Annual Meeting of the International Continence Society, Christchurch, New Zealand
46. Kalsi V, Popat RB, Apostolidis A et al. (2006) Cost-consequence analysis evaluating the use of Botulinum Neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49: 519-527